Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 260 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RSV Respiratory Syncytial Virus Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)

NCT06077149
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV vaccine
Biological
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 15, 2026, 2:58 PM EDT
Active, not recruiting No phase listed Observational

A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) Disease

NCT06077968
View directory record Official record
Conditions
Respiratory Syncytial Viruses
Interventions
Prior standard of care receipt of Pfizer's ABRYSVO vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 15, 2026, 2:58 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

NCT04980391
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 49 Years · Female only
Enrollment
384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

NCT03636906
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV (GSK3389245A) lower dose formulation vaccine, RSV (GSK3389245A) higher dose formulation vaccine, GSK's multicomponent meningococcal B vaccine, Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine, GSK's pneumococcal polysaccharide conjugate vaccine, GSK's meningococcal group A, C, W-135 and Y conjugate vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 7 Months
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Nampa, Idaho • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children

NCT02707523
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Azithromycin 10 mg, Azithromycin 20mg, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 16 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

NCT02419391
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MVA BN RSV, Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 15, 2026, 2:58 PM EDT
Completed No phase listed Observational

Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment

NCT05268939
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza Type B, RSV Infection
Interventions
LumiraDx SARS-CoV-2 & Flu A/B test, LumiraDx SARS-CoV-2 & RSV test
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
Not listed
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Cullman, Alabama • Encinitas, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 15, 2026, 2:58 PM EDT
Active, not recruiting Not applicable Interventional

Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

NCT05864118
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Respiratory pathogen panel PCR test, COVID-19 antibody test
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.

NCT02593071
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV-F Vaccine, Phosphate Buffer Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
10
States / cities
Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 15, 2026, 2:58 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT06252285
View directory record Official record
Conditions
RSV Immunisation
Interventions
RSVt Vaccine, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 21 Months
Enrollment
6,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Guntersville, Alabama • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

NCT02115815
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Placebo, RSV sF 20 mcg, MEDI7510 (20 mcg RSV sF), RSV sF 50 mcg, MEDI7510 (50 mcg RSV sF), RSV sF 80 mcg, MEDI7510 (80 mcg RSV sF)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
60 Years to 99 Years
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 15, 2026, 2:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)

NCT06325332
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Nirsevimab
Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
0 Days to 12 Months
Enrollment
49,680 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects

NCT04871724
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Fluconazole
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

NCT05900154
View directory record Official record
Conditions
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Interventions
RSVpreF 120 µg, RSVpreF 60 µg
Biological
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • Rolling Hills Estates, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 15, 2026, 2:58 PM EDT
Completed No phase listed Observational

An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF

NCT01455402
View directory record Official record
Conditions
Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure
Interventions
Not listed
Lead sponsor
MedImmune LLC
Industry
Eligibility
50 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Oct 15, 2026, 2:58 PM EDT
Recruiting Phase 2 Interventional

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

NCT07214571
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
S-337395, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
37
States / cities
Los Angeles, California • Modesto, California • Toluca Lake, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

NCT06134648
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus
Interventions
RSV/hMPV vaccine candidate Dose L, RSV/hMPV vaccine candidate Dose A, RSV/hMPV vaccine candidate Dose B, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
646 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
10
States / cities
Los Alamitos, California • Los Angeles, California • Rolling Hills Estates, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers

NCT01355016
View directory record Official record
Conditions
Drug Safety, Respiratory Syncytial Virus Infections
Interventions
MDT-637
Drug
Lead sponsor
MicroDose Therapeutx, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS

NCT04071158
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV Vaccine, Tdap, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
713 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
16
States / cities
Stockbridge, Georgia • Honolulu, Hawaii • Wichita, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Airway Obstruction in Infants With Lower Respiratory Infections

NCT00435994
View directory record Official record
Conditions
Bronchiolitis, Respiratory Syncytial Virus Infections
Interventions
Inhaled primatene will be given as a breathing treatment, Nasal Washing
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 2 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

NCT06143046
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
0 Years to 40 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
22
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers

NCT02668367
View directory record Official record
Conditions
Pharmacokinetics, Healthy Volunteers
Interventions
BTA-C585 oral capsules, BTA-C585 matching placebo
Drug
Lead sponsor
Biota Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

NCT05879107
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, PCV20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
1,113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
20
States / cities
Guntersville, Alabama • Phoenix, Arizona • Huntington Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 15, 2026, 2:58 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children

NCT00767416
View directory record Official record
Conditions
Healthy
Interventions
MEDI-559, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Month to 23 Months
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
75
States / cities
Greenville, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 15, 2026, 2:58 PM EDT